Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Oct;44(10):2811-5.
doi: 10.1128/AAC.44.10.2811-2815.2000.

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

Affiliations
Clinical Trial

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

M D Pescovitz et al. Antimicrob Agents Chemother. 2000 Oct.

Abstract

The pharmacokinetics of an orally administered valine ester of ganciclovir (GCV), valganciclovir (VGC), were studied. These were compared to the pharmacokinetics of oral and intravenous GCV. Twenty-eight liver transplant recipients received, in an open-label random order with a 3- to 7-day washout, each of the following: 1 g of oral GCV three times a day; 450 mg of VGC per os (p.o.) once a day (q.d.); 900 mg of VGC p.o. q.d.; and 5 mg of intravenous (i.v.) GCV per kg of body weight q.d., given over 1 h. GCV and VGC concentrations were measured in blood over 24 h. One-sided equivalence testing was performed to test for noninferiority of 450 mg of VGC relative to oral GCV (two-sided 90% confidence interval [CI] > 80%) and nonsuperiority of 900 mg of VGC relative to i.v. GCV (two-sided 90% CI < 125%). The exposure of 450 mg of VGC (20.56 microg. h/ml) was found to be noninferior to that of oral GCV (20.15 microg. h/ml; 90% CI for relative bioavailability of 95 to 109%), and the exposure of 900 mg of VGC (42.69 microg. h/ml) was found to be nonsuperior to that of i.v. GCV (47.61 microg. h/ml; 90% CI = 83 to 97%). Oral VGC delivers systemic GCV exposure equivalent to that of standard oral GCV (at 450 mg) or i.v. GCV (at 900 mg of VGC). VGC has promise for effective CMV prophylaxis or treatment with once-daily oral dosing in transplant recipients.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Mean plasma pharmacokinetic profiles following dosing with i.v. GCV, oral GCV, and VGC. Solid symbols are mean plasma drug concentrations (on a log scale) over the 24-h dosing interval of GCV after i.v. GCV (⧫), oral GCV (●), 450 mg of oral VGC (■), or 900 mg of oral VGC (▴). Open symbols are plasma VGC concentrations after 450 mg of oral VGC (□) and 900 mg of oral VGC (▵). Plasma VGC concentrations were only measured and reported for patients dosed with VGC. A dose-dependent increase in GCV concentration was seen after dosing with VGC. The amount of unmetabolized VGC was substantially less than that of GCV (<3%).

References

    1. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167–176. - PubMed
    1. Chan R, LaFargue J, Reeve R, Tam Y, Tarnowski T. An HPLC method for the determination of diastereomeric prodrug RS-79070-004 in human plasma. J Pharm Biomed Anal. 1999;21:647–656. - PubMed
    1. Chu F, Kiang C-H, Sung M-L, Huang B, Reeve R L, Tarnowski T. A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. J Pharm Biomed Anal. 1999;21:657–667. - PubMed
    1. Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. - PubMed
    1. Drew W L, Stempien M J, Andrews J, Shadman A, Tan S J, Miner R, Buhles W. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. J Infect Dis. 1999;179:1352–1355. - PubMed

Publication types